Murphy Capital Management Inc. Sells 1,425 Shares of SPDR S&P Biotech ETF (XBI)

Murphy Capital Management Inc. trimmed its position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 7.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 17,920 shares of the exchange traded fund’s stock after selling 1,425 shares during the quarter. Murphy Capital Management Inc.’s holdings in SPDR S&P Biotech ETF were worth $1,285,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the company. JPMorgan Chase & Co. lifted its stake in shares of SPDR S&P Biotech ETF by 98.7% in the third quarter. JPMorgan Chase & Co. now owns 3,265,715 shares of the exchange traded fund’s stock worth $313,084,000 after acquiring an additional 1,622,372 shares during the period. Wells Fargo & Company MN lifted its stake in shares of SPDR S&P Biotech ETF by 10.0% in the third quarter. Wells Fargo & Company MN now owns 1,716,647 shares of the exchange traded fund’s stock worth $164,576,000 after acquiring an additional 156,483 shares during the period. Rafferty Asset Management LLC lifted its stake in shares of SPDR S&P Biotech ETF by 114.1% in the third quarter. Rafferty Asset Management LLC now owns 941,464 shares of the exchange traded fund’s stock worth $90,258,000 after acquiring an additional 501,695 shares during the period. First Republic Investment Management Inc. lifted its stake in shares of SPDR S&P Biotech ETF by 1.6% in the third quarter. First Republic Investment Management Inc. now owns 523,329 shares of the exchange traded fund’s stock worth $50,171,000 after acquiring an additional 8,257 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. lifted its stake in shares of SPDR S&P Biotech ETF by 306.3% in the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 357,610 shares of the exchange traded fund’s stock worth $34,281,000 after acquiring an additional 269,595 shares during the period.

SPDR S&P Biotech ETF stock opened at $82.68 on Friday. SPDR S&P Biotech ETF has a one year low of $64.38 and a one year high of $101.55.

ILLEGAL ACTIVITY NOTICE: “Murphy Capital Management Inc. Sells 1,425 Shares of SPDR S&P Biotech ETF (XBI)” was first published by Fairfield Current and is the sole property of of Fairfield Current. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.fairfieldcurrent.com/news/2019/02/10/murphy-capital-management-inc-sells-1425-shares-of-spdr-sp-biotech-etf-xbi.html.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Featured Article: Google Finance

Receive News & Ratings for SPDR S&P Biotech ETF Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com’s FREE daily email newsletter.